Hansa Biopharma
26.18
SEK
-2.89 %
HNSA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients. Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.
Read moreFinancial calendar
Interim report Q1'25
General meeting '25
Interim report Q2'25
Redeye: Hansa Biopharma - Ends 2024 on a soft note
Hansa Biopharma AB: Hansa Biopharmas bokslutskommuniké för januari-december 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits